{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Adenocarcinoma","Anticoagulants","Colon Cancer","Colonic Neoplasms"],"disease":["Adenocarcinoma","Anticoagulants","Colon Cancer","Colonic Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2037746"],"location":["United States"],"study_start_month":["12"],"keyword":["RECIST","Targeted therapy","Coagulation-dependent","Tissue factor","Protein C","Leucovorin","RNAPc2","FOLFIRI","Colorectal carcinoma (CRC)","XELOX","Metastatic colorectal carcinoma (mCRC)","FOLFOX","5-FU-based chemotherapy","Factor VIIa"],"repository":["ECRIN MDR"],"study_status":["Suspended"],"additional_accession":[]},"is_claimable":false,"name":"Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer","description":"This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line treatment of metastatic colorectal carcinoma in combination with contemporary 5-FU-based chemotherapy.","dates":{"creation":"2006-12-15"},"accession":"2037746","cross_references":{"ClinicalTrials___gov":["NCT00443573"]}}